The author initially shows the OMS reports on the cardiovascular deaths (30) through the world. The annual numbers reaches million people delineating a real pandemy that urges primary and secondary preventive actions and effective medications therapeutic measures.
The coronary artery disease and the stroke are responsible for 80 of the cardiovascular deaths related to risk factors such as: arterial hypertension, hyperlipidemia, diabetes mellitus, smoking and others. The hypertension therapy needs the risk factors related detection to choose the most efficacious drug with the lowest metabolic parameters burden.
In the last 20 years several guidelines reports supports the drugs utilization by demonstration of its efficacy and safety allover the years. Briefly, all the medications used actually reduces the blood pressure (BP) in a greater or lower degree, with evident benefits.
Recently, the INSIGH Study, compared of Nifedipine in a long-acting gastrointestinal transport system (GITS) (OROS in Brazil) in a single daily dose with the hydrochlorothiazide/amiloride association in a large cohort. The main results shows a mean systolic and diastolic BP reduction from 173 ± 14 and 99 ± 8 to 138 ± 12 and 82 ±7 mmHg at the study end, and achieved in 71 of the patients in 20 treatment weeks only through monotherapy. The total morbidity and mortality (primary and secondary endpoints) were 24,6, without difference between groups. The estimated risk for new primary cardiovascular events at the end of the treatment was reduced in 50.
These findings allows the conclusion that Nifedipine GITS and the diuretics agents allowed an effective BP control and the first of these agents may considered the first choice for arterial hypertension therapy.